AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2972549
Drug: Dexchlorpheniramine maleate
RxNorm normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine maleate (6 mg)
Trial: 23611305
Drug: Older cousin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older cousin with drug abuse (DA)
Trial: 20369616
Drug: Remaxol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaxol infusion solution
Trial: 17578978
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg before surgery and 200 mg every 12 h for 14 days postoperatively
Trial: 15589464
Drug: Fenoldopam infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam infusion at 0.025 microg/kg/min titrated to 0.1 microg/kg/min for 48 hours post-op
Trial: 15589464
Drug: Antibody induction
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody induction (AI) using antithymocyte globulin (AT-G(r))
Trial: 12110157
Drug: Diagnostic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic and treatment algorithms to optimize antibiotic use in nursing homes
Trial: 2157313
Drug: Ibopamine 200
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 200 mg plus Furosemide 40 mg
Trial: 16251617
Drug: NaFeEDTA-fortified fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA-fortified fish sauce (9 mmol (500 mg) Fe/L) for 18 months
Trial: 9632998
Drug: Potent combination
RxNorm normalized name: Corticosteroids, potent, other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent combination antiretroviral therapy
Trial: 9004781
Drug: Zinc Acexamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc Acexamate (600 mg/d)
Trial: 31660706
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg/d)
Trial: 6398312
Drug: Thymopentin administered
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin administered subcutaneously (s.c.)
Trial: 6398312
Drug: Thymopentin administered
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin administered intravenously (i.v.)
Trial: 29932784
Drug: Internet-based mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based mindfulness-based cognitive therapy (eMBCT)
Trial: 24994476
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (n = 8)
Trial: 24994476
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n = 11)
Trial: 14515443
Drug: ALL-BFM 90
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALL-BFM 90 protocol chemotherapy for 2 years
Trial: 8879341
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg)
Trial: 8879341
Drug: Bisoprolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (2.5 to 10 mg)/Hydrochlorothiazide (HCTZ) 6.25
Trial: 8879341
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 20 mg)
Trial: 31245907
Drug: Iguratimod plus
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod plus corticosteroid (diprospan, intramuscular injection, 25 mg, twice daily for 24 weeks)
Trial: 22409849
Drug: Cryoablation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation treatment
Trial: 17699388
Drug: Low-dosage enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage enoxaparin
Trial: 8072077
Drug: Oral methyltestosterone
RxNorm normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methyltestosterone (2 different commercial preparations) for 1 month
Trial: 31402742
Drug: Inverse prism
RxNorm normalized name: Inversedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse prism (IP) therapy
Trial: 31402742
Drug: Conventional prism
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional prism (CP) therapy
Trial: 21355718
Drug: Intradermal microneedle
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal microneedle delivery of insulin lispro (IL)
Trial: 18536954
Drug: Cinacalcet (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (15 then 30 mg/day)
Trial: 16890577
Drug: Lopinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily)
Trial: 16890577
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg twice daily (after dose adjustment)
Trial: 16890577
Drug: Lamotrigine 50
RxNorm normalized name: lamotrigine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 50 mg once daily on days 1 and 2 and 100 mg twice daily on day 3 through day 10
Trial: 11359886
Drug: Amorphous hydrogel
RxNorm normalized name: HYDROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorphous hydrogel dressing (Intrasite Gel)
Trial: 8267175
Drug: Fentanyl 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5 ng/mL
Trial: 8267175
Drug: Alfentanil 28.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 28.8 ng/mL
Trial: 3311051
Drug: Triamcinolone subacromial
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone subacromial bursa injection
Trial: 3311051
Drug: Naproxen therapy
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen therapy
Trial: 30842172
Drug: Single-dose RSB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose RSB analgesia
Trial: 27398889
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine for 72 hours
Trial: 25736126
Drug: DEX 0.3
RxNorm normalized name: Ciprodex 0.3%-0.1% Otic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0.3 micro;g/kg followed by propofol 1 mg/kg (group D)
Trial: 25736126
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg (group C)
Trial: 19906340
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole (2-15 mg/d)
Trial: 19906340
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole (in risperidone subgroup)
Trial: 19906340
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole (in quetiapine subgroup)
Trial: 17692117
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion (0.05 units/kg/h)
Trial: 12487852
Drug: (186)Re-lipiodol (RL)
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (186)Re-lipiodol (RL) administered at doses ranging from 1 110 MBq to 2 220 MBq per patient depending on tumor volume.
Trial: 7636556
Drug: Single 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20-mg IV dose of dexamethasone plus single 32-mg IV dose of ondansetron
Trial: 7636556
Drug: Single 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20-mg IV dose of dexamethasone plus single 24-mg IV dose of ondansetron
Trial: 7636556
Drug: Single 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20-mg IV dose of dexamethasone plus single 8-mg IV dose of ondansetron
Trial: 2236435
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/Kg b.i.d.)
Trial: 27093
Drug: Rolaids (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolaids (2 tablets)
Trial: 27093
Drug: Di-Gel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Di-Gel (2 tablets)
Trial: 27093
Drug: Maalox liquid
RxNorm normalized name: Maalox Max Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox liquid (15 ml)
Trial: 27093
Drug: Conquel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conquel (2 tablets)
Trial: 27784414
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Insomnia Therapy (CBT-I)
Trial: 27784414
Drug: Quasi-desensitization Control
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quasi-desensitization Control (CTRL) therapy
Trial: 27784414
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (escitalopram, sertraline, desvenlafaxine) with either CBT-I or CTRL
Trial: 9307129
Drug: Prior administration
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior administration of dextromethorphan (a N‐methyl‐D‐aspartate receptor antagonist).
Trial: 8458045
Drug: Transnasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal butorphanol (0.25, 0.5, 1, or 2 mg)
Trial: 28010731
Drug: Heavy clinical
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy clinical workload, shift patterns of work, inadequate number of trained staff, time and setting of consent seeking, non-availability of research staff out of hours, parents' concerns about experimental medicine
Trial: 21660402
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (2 mg/kg/d, maximum 20 mg in 2 divided doses, for 5 days)
Trial: 18434918
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system worn for 4 hours
Trial: 18434918
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system worn for 6 hours
Trial: 18434918
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (various doses: 10, 15, 20, or 30 mg) worn for 9 hours
Trial: 16544177
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg deoxyspergualin (DSG)
Trial: 16544177
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg deoxyspergualin (DSG)
Trial: 16544177
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of deoxyspergualin (DSG)
Trial: 10718390
Drug: Synergistic sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergistic sedation with low-dose midazolam and propofol (group II), median dose of 2 mg midazolam and median 100 mg propofol (IQR 53 to 145) with a maximal bolus of 50 mg.
Trial: 10718390
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination of midazolam and nalbuphine (group I), median dose of 9 mg midazolam (IQR 6 to 12) and median 20 mg nalbuphine (IQR 10 to 20).
Trial: 1350366
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (50 micrograms morning and evening)
Trial: 1350366
Drug: Theophylline-ketotifen association
RxNorm normalized name: ketotifen / theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-ketotifen association (300 mg and 1 mg morning and evening)
Trial: 27525532
Drug: SC administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC administration of 20 mcg of teriparatide every 12 hours until discharge
Trial: 22154591
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy plus adjuvant chemotherapy
Trial: 16263827
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg melatonin
Trial: 12610739
Drug: Hydrochloride salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochloride salt (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Trial: 12610739
Drug: Cinchona alkaloid
RxNorm normalized name: Cinchona alkaloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Trial: 12610739
Drug: Hydrochloride salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochloride salt (8 mg/kg quinine base every 8 h by intrarectal administration)
Trial: 12610739
Drug: Cinchona alkaloid
RxNorm normalized name: Cinchona alkaloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by intrarectal administration)
Trial: 8629065
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy alone
Trial: 8629065
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy plus antibiotics
Trial: 8629065
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy followed by diethylcarbamazine citrate (DEC)
Trial: 8629065
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy plus antibiotics followed by DEC
Trial: 8629065
Drug: Hygienic measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygienic measures combined with good foot care and local antibiotic/antifungal cream application
Trial: 15927414
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (controls)
Trial: 29081179
Drug: ILK-CSC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILK-CSC injection (1×10^5 cells/30 μl)
Trial: 29081179
Drug: Ad-null-CSC injection
RxNorm normalized name: Nullo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad-null-CSC injection (1×10^5 cells/30 μl)
Trial: 23438054
Drug: Collagen/ORC/silver therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen/ORC/silver therapy
Trial: 23438054
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (standard treatment)
Trial: 11360851
Drug: Xylose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylose 5% infusion
Trial: 11360851
Drug: Electrolyte infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte infusion
Trial: 9428058
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) treatment for 4 weeks
Trial: 8098392
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of 125 mL of an aminoacid mixture (Synthamin 14 without electrolytes) over 5 min (2.1 g per min)
Trial: 8098392
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of 50 mL of aminoacids over 5 min
Trial: 3318991
Drug: Reality orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reality orientation followed by reminiscence therapy
Trial: 24557441
Drug: EMLA(®) cream
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA(®) cream
Trial: 24557441
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (EMLA(®) cream and traditional anesthetic)
Trial: 20390497
Drug: m-DOT (modified-directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-DOT (modified-directly observed therapy)
Trial: 17522928
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: overnight infusion and a bolus of colloid before induction of anesthesia, followed by a bolus just before pneumoperitoneum (PP)
Trial: 17522928
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: overnight infusion and a colloid bolus before anesthesia
Trial: 17522928
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: received only infusion during operation
Trial: 10227461
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and autologous stem cell support
Trial: 10227461
Drug: Melphalan-prednisone (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan-prednisone (initial therapy)
Trial: 6337618
Drug: Sulconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulconazole 1% cream
Trial: 30556374
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded group (loaded on the same day as implant insertion)
Trial: 30556374
Drug: Conventionally loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally loaded group (loaded 3 months after implant insertion)
Trial: 24669841
Drug: Recombinant IFN‐γ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant IFN‐γ (rIFN‐γ, 100 μg s.c., thrice a week) for 2 weeks
Trial: 24669841
Drug: Standard antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antifungal therapy
Trial: 22982081
Drug: Problem-Solving Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Therapy (PST: in-person or telehealth delivery)
Trial: 18973065
Drug: Rivastigmine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (1.5 mg once a day increment over 4 weeks to 3 mg twice daily)
Trial: 16076046
Drug: Exogenous activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous activated protein C (drotrecogine alpha) included in therapy for sepsis
Trial: 12602460
Drug: Fosinopril 5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 5-20 mg/day
Trial: 9882083
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexketoprofen trometamol 25 mg
Trial: 9882083
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexketoprofen trometamol 12.5 mg
Trial: 9882083
Drug: dipyrone 575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dipyrone 575 mg
Trial: 7925220
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g boiled carrots
Trial: 7925220
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g boiled carrots
Trial: 7925220
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g boiled carrots
Trial: 7925220
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g boiled carrots with lactic acid
Trial: 2635834
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SI)
Trial: 2635834
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OI)
Trial: 24841105
Drug: Sodium pyruvate
RxNorm normalized name: Sodium Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium pyruvate (0.1 g·kg(‐1) of body mass)
Trial: 3118755
Drug: Nitroglycerin discs
RxNorm normalized name: DISC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin discs (30 mg)
Trial: 24187865
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy at acupoint until appearance of skin eruptions
Trial: 24187865
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy along channel until appearance of skin eruptions
Trial: 24187865
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy at acupoint without appearance of skin eruptions
Trial: 24187865
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy along channel without appearance of skin eruptions